For expression of genes involved in vascular morphogenesis and maturation, it was reported that low VEGFB and high FLT1 in primary tumours and high ACVRL1 levels in liver metastases were associated with enhanced OS of CRC patients with liver metastases treated with bevacizumab plus chemotherapy [32]. The gene discussed is VEGFB; the disease is neoplasm.